Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by MyKnighton Jan 15, 2020 11:18am
44 Views
Post# 30555585

RE:🚨🚨🚨NO NEW DRUGS IN PIPELINE🚨🚨🚨

RE:🚨🚨🚨NO NEW DRUGS IN PIPELINE🚨🚨🚨 They have Both rights on the patent on the planet.

Now is not the time to diluate revenu.
  • First GVHD on the planet(1 Billios a year)
  • Then Pain killer to complete against Opiod.(really smart move)(50 Billions a year)

The Treatment of acute and chronic pain has nothing to do with Talent only the GVHD .

So the pain market is only own by Kaly no revenu sharing for this one.

SIMPLY incredible.

People saying they have other drugs are flat out lying to your face. They only have the GVHD drug and can't afford to begin testing on the final patient for the Phase 2 trial. Kalytera stated, "Kalytera has agreed to put its program in treatment of acute and chronic pain on hold, and any further payments and expenses in connection with the pain program, and the maintenance of any associated agreements, are subject to discussions with and the approval of the former shareholders of Talent".
Bullboard Posts